BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 29523783)

  • 1. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.
    Katodritou E; Terpos E; Delimpasi S; Kotsopoulou M; Michalis E; Vadikolia C; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Vadikolia C; Michael M; Kalpadakis C; Gougopoulou T; Prokopiou C; Kaiafa G; Christoulas D; Gavriatopoulou M; Giannopoulou E; Labropoulou V; Verrou E; Kastritis E; Konstantinidou P; Anagnostopoulos A; Dimopoulos MA
    Blood Cancer J; 2018 Mar; 8(3):31. PubMed ID: 29523783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
    Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.
    Jurczyszyn A; Radocha J; Davila J; Fiala MA; Gozzetti A; Grząśko N; Robak P; Hus I; Waszczuk-Gajda A; Guzicka-Kazimierczak R; Atilla E; Mele G; Sawicki W; Jayabalan DS; Charliński G; Szabo AG; Hajek R; Delforge M; Kopacz A; Fantl D; Waage A; Avivi I; Rodzaj M; Leleu X; Richez V; Knopińska-Posłuszny W; Masternak A; Yee AJ; Barchnicka A; Druzd-Sitek A; Guerrero-Garcia T; Liu J; Vesole DH; Castillo JJ
    Br J Haematol; 2018 Mar; 180(6):831-839. PubMed ID: 29315478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.
    Royer B; Minvielle S; Diouf M; Roussel M; Karlin L; Hulin C; Arnulf B; Macro M; Cailleres S; Brion A; Brechignac S; Belhadj K; Chretien ML; Wetterwald M; Chaleteix C; Tiab M; Leleu X; Frenzel L; Garderet L; Choquet S; Fuzibet JG; Dauriac C; Forneker LM; Benboubker L; Facon T; Moreau P; Avet-Loiseau H; Marolleau JP
    J Clin Oncol; 2016 Jun; 34(18):2125-32. PubMed ID: 27114594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group.
    Katodritou E; Kastritis E; Dalampira D; Delimpasi S; Spanoudakis E; Labropoulou V; Ntanasis-Stathopoulos I; Gkioka AI; Giannakoulas N; Kanellias N; Papadopoulou T; Sevastoudi A; Michalis E; Papathanasiou M; Kotsopoulou M; Sioni A; Triantafyllou T; Daiou A; Papadatou M; Kyrtsonis MC; Pouli A; Kostopoulos I; Verrou E; Dimopoulos MA; Terpos E
    Am J Hematol; 2023 May; 98(5):730-738. PubMed ID: 36869876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
    Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
    Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma.
    Iriuchishima H; Ozaki S; Konishi J; Matsumoto M; Murayama K; Nakamura F; Yamamoto G; Handa H; Saitoh T; Nagura E; Shimizu K; Nojima Y; Murakami H
    Acta Haematol; 2016; 135(2):113-21. PubMed ID: 26505781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
    Zannetti BA; Tacchetti P; Pantani L; Gamberi B; Tosi P; Rocchi S; Cellini C; Ronconi S; Pezzi A; Mancuso K; Rizzello I; Caratozzolo I; Martello M; Dozza L; Cavo M; Zamagni E
    Ann Hematol; 2017 Dec; 96(12):2071-2078. PubMed ID: 29063955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation].
    Li WJ; Wang FR; Wen L; Chen Y; Chen H; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2020 Oct; 59(10):801-806. PubMed ID: 32987483
    [No Abstract]   [Full Text] [Related]  

  • 10. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.
    Yu T; Xu Y; An G; Tai YT; Ho M; Li Z; Deng S; Zou D; Yu Z; Hao M; Anderson KC; Qiu L
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e652-e659. PubMed ID: 32624447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
    Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
    Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
    Wang H; Zhou H; Zhang Z; Geng C; Chen W
    Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.
    Pagano L; Valentini CG; De Stefano V; Venditti A; Visani G; Petrucci MT; Candoni A; Specchia G; Visco C; Pogliani EM; Ferrara F; Galieni P; Gozzetti A; Fianchi L; De Muro M; Leone G; Musto P; Pulsoni A;
    Ann Oncol; 2011 Jul; 22(7):1628-1635. PubMed ID: 21252060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Retrospective analysis on therapeutic effect of autologous hematopoietic stem cell transplantation in multiple myeloma patients].
    Wang J; Fu CC; Wu DP; Sun AN; Xue SL; Xin X; Hu XH; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Han Y; Ma X; He GS; Chang WR; Chen SN
    Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(2):114-8. PubMed ID: 23648347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
    Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.
    Gowda L; Shah M; Badar I; Bashir Q; Shah N; Patel K; Kanagal-Shamanna R; Mehta R; Weber DM; Lee HC; Manasanch EE; Shah A; Thomas SK; Parmar S; Nieto Y; Orlowski RZ; Champlin R; Qazilbash MH
    Bone Marrow Transplant; 2019 Jul; 54(7):1089-1093. PubMed ID: 30446740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160).
    Jung SH; Lee JJ; Kim K; Suh C; Yoon DH; Min CK; Sohn SK; Choi CW; Lee HS; Kim HJ; Shin HJ; Bang SM; Yoon SS; Park SK; Yhim HY; Kim MK; Jo JC; Mun YC; Lee JH; Kim JS;
    Oncotarget; 2017 Oct; 8(45):79517-79526. PubMed ID: 29108331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.
    Muchtar E; Gertz MA; Kumar SK; Lacy MQ; Dingli D; Buadi FK; Grogan M; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Gonsalves W; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Dispenzieri A
    Blood; 2017 Apr; 129(15):2111-2119. PubMed ID: 28126928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.